TO STUDY EFFECT OF DURALABHADI LEHA IN TAMAKASHWAS(CHILDHOOD ASTHMA) IN CHILDRE

Phase 2

• Conditions: Health Condition 1: J452- Mild intermittent asthma

• Registration Number: CTRI/2024/05/066714
• Lead Sponsor: Dr Pranjali Undre

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 27 May 2024

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1) Children having symptoms of Tamaka Shwasa as mentioned by Charak :

Shwasakruchhrata (Dyspnea)

Kasa (Cough)

Ghur-Ghurak Shabda (Wheezing)

Kashten Shleshma Moksha (Difficulty in Expectorant)

Peenas

2)Children of age Group 1 year to 12 years.

3) Children who has a family history of asthma with a symptoms of Tamaka

Shwasa.

4)Chidren who are ready to participate in the clinical trial by giving informed

written consent.

Exclusion Criteria

1)Patients having life threatening illness and who are bed ridden.

2)Patients having any congenital respiratory and GIT abnormality.

3)Patients who require surgical management.

4)Patients with known case of Pulmonary Tuberculosis, Pleural effusion,

Emphysema, Bronchial Carcinoma, Status asthmatics

5)Patients having other systemic major illness like Immunocompromise

diseases, Cardiac Disease, Renal Failure.

6)Patient with severe Asthmatic condition who needs Emergency

treatment.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To decrease breathing difficulty and cough in childrenTimepoint: 7 Days study with followup on 4th day and 7th day <br/ ><br>(0,4,7 Days)

Secondary Outcome Measures

Name	Time	Method
To study the Adverse effect of Duralabhadi <br/ ><br>leha, if anyTimepoint: 7 Days study with followup on 4th day and 7th day <br/ ><br>(0,4,7 Days)